long half-life and large variability [Regulatives / Guidelines]

posted by Achievwin – US, 2020-08-12 15:22 (351 d 17:39 ago) – Posting: # 21864
Views: 1,066

Welcome to the home of funky and funny pharmacokinetics where "Garbage in Gospel out" is day of life.

1. allowing long washout periods have seen studies with 4 -5 months washout.
2. other choice we can imagine is Two stage adaptive study design and including ANCOA in place of ANOVA...

want to know what other experts think?

» In short:
  • pretty long half-life
  • huge total variablity (i.e. within + between variability)
  • total variability is expected to be explained to some degree by some covariates

Complete thread:

Activity
 Admin contact
21,592 posts in 4,514 threads, 1,532 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time: Friday 09:02 CEST (Europe/Vienna)

It is a capital mistake to theorise before one has data.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5